Analystreport

Actinium Pharmaceuticals, Inc. (NYSE: ATNM) had its "buy" rating re-affirmed by analysts at William Blair.

Actinium Pharmaceuticals, Inc. (Delaware)  (ATNM) 
NASDAQ:AMEX Investor Relations: ir.actiniumpharma.com